Synergy Pharmaceuticals Inc. SGYP, a developer of new drugs to
treat gastrointestinal diseases and disorders, today announced the
planned spin-off of its FV-100 assets into a separate publicly traded
company. Synergy's newly formed subsidiary, ContraVir Pharmaceuticals,
Inc., the company which will hold the FV-100 assets (“ContraVir”), has
filed a Form 10 Registration Statement (“Form 10”) with the U.S.
Securities and Exchange Commission. The separation contemplates a 100%
distribution of the ContraVir shares of common stock, now held by
Synergy, to Synergy's stockholders on a pro-rata basis.
"The filing of the Form 10 by ContraVir is an important step in the
process of developing and establishing our FV-100 assets as a new,
stand-alone company with its
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in